SUPPLEMENTAL MATERIALS

Supplemental Table S1. Number and Proportion of Patients With EIMs at Baseline in Induction/Maintenance Studies or Open-Label Extensions Included in Pooled Analysis*

Study	Placebo n/N (%)	Adalimumab n/N (%)
CLASSIC-I (NCT00055523)[13]/ CLASSIC-II (NCT00055497)[11]	48/73 (66)	157/225 (70)
GAIN (NCT00105300)[15]/ ADHERE (NCT00195715)[21]†	109/166 (66)	101/158 (64)
M04-729 Japan (NCT00445939)/ M06-837 (NCT00445432)[19,41]	8/23 (35)	17/67 (25)
CHARM (NCT00077779)[12]/ ADHERE (NCT00195715)[20]†	106/259 (41)	296/517 (57)
EXTEND (NCT00348283)[17]	26/65 (40)	43/64 (67)
IMAgINE 1 (NCT00409682)[14]/ IMAgINE 2 (NCT00686374)[22]‡	NA	37/121 (31)
CARE (NCT00409617)[18]	NA	486/942 (52)
Patients with EIMs/total patients (n/N)	297/586 (51)	1137/2094 (54)

EIM, extraintestinal manifestation; NA, not applicable.

*Intent-to-treat populations.

†Patients from GAIN and CHARM could enroll in ADHERE.

‡The EIM analysis only included patients ≥13 years of age with Crohn's Disease Activity Index data. IMAgINE 2 is ongoing.

n/N: patients with EIMs at baseline/total intent-to-treat population.

Supplemental Figure S1. Patient disposition from adalimumab studies included in this analysis. Patient numbers at baseline were from the intent-to-treat population; patient numbers from the 6-month (weeks 20–26) and 1-year (weeks 52–56) time points were from patients remaining at follow-up. The dashed lines represent the end of the induction studies and the beginning of the maintenance or extension studies. ADA, adalimumab; DB, double blind; OL, open label; PBO, placebo.